CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo

The Centers for Medicare and Medicaid Services may experiment with Indication-based pricing for chimeric antigen receptor T cell (CAR-T) therapies in an upcoming demonstration conducted by its Center for Medicare and Medicaid Innovation.

The demonstration is likely to be carried out in Medicare and would mark the first time CMMI has directly tackled...